Affiliation:
1. Rostov State Medical University; Kuban State Medical University
2. SM-Clinic
Abstract
Introduction. The instructions for the drug dupilumab indicate that the administration of a single loading dose on the first day leads to the rapid achievement of clinically effective concentrations within 2 weeks, which we saw in the example of our patient and her real clinical response to the first injection. Presentation of a clinical case. Under our medical supervision was a 17-year-old patient with severe atopic dermatitis, resistant to traditional therapy. Heredity for allergic pathology is burdened: the girl’s mother suffers from pollen allergy. Initially before the start of therapy: SCORAD — 88 points, EASI — 48.8 points, IGA — 4, blood eosinophils — 11 % (1188 cells/ml), total IgE — 1102.0 IU/ml; the content of nitric oxide in exhaled air (FeNO) is 30 ppb. On April 28, 2021, the patient was administered dupilumab at a dose of 600 mg. Assessment of atopic dermatitis control in points upon admission to the hospital 2 weeks after the first administration of dupilumab: on the SCORAD scale — 44.5 points; EASI — 13.8 points; IGA — 2 points, eosinophils — 9 % (1070 cells/ml); total IgE — 840 IU/ml; FeNO — 5 ppb. Conclusion. This clinical observation clearly illustrates the fact that patients with severe atopic dermatitis who don’t respond to first-line therapy can achieve positive clinical results after the first use of a recombinant human monoclonal antibody (IgG4).
Publisher
Association of Pediatric Allergologists and Immunologists of Russia
Reference21 articles.
1. Clinical guidelines Atopic dermatitis. 2020. (In Russ.) https://www.nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf
2. Hyoger Peter G. Detskaya dermatologiya / per. s nem. pod red. A. A. Kubanovoj, A. N. L’vova. Moskva : Izdatel’stvo Panfilova ; BINOM. Laboratoriya znanij, 2013; s. 162–163. (In Russ.)
3. Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. The Journal of Dermatology. 2021; 48: 130–139. doi: 10.1111/1346-8138.15664
4. Churyukina EV. Dupilumab: aspects of use in severe bronchial asthma in real clinical practice. Practical pulmonology. 2022; 2: 3–10. (In Russ.)] doi: 10.24412/2409-6636-2022-12937
5. Kuzubova NA, Titova ON. T2-associated diseases: focus on the comorbid patient. Meditsinskiy sovet = Medical Council. 2020; (17): 57–64. (In Russ.) doi: 10.21518/2079-701X-2020-17-57-64